Bai Li Tian Heng (688506.SH): SI-B036 bispecific antibody injection approved for clinical trials in advanced solid tumors.

Zhtng Cijng APP News, Baili Tianheng (688506.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA). The company's independently developed innovative biological drug SI-B036 bispecific antibody injection clinical trial has been approved, allowing the drug to be used as a monotherapy in clinical trials for advanced solid tumors.